David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Tijdelijke apoptose-inhibitie donorstamcellen verbetert hematopoietische stamceltransplantatie
jan 2018 | Stamceltransplantatie